Newron Pharmaceuticals SpA (CH:NWRN)
:NWRN
Want to see CH:NWRN full AI Analyst Report?
NWRN Stock Chart & Stats
CHF16.44
-CHF0.12(-1.32%)
At close: 4:00 PM EST
CHF16.44
-CHF0.12(-1.32%)
Day’s Range― - ―
52-Week RangeCHF6.50 - CHF31.85
Previous CloseN/A
Volume17.86K
Average Volume (3M)170.30K
Market Cap
CHF254.25M
Enterprise ValueCHF298.27M
Total Cash (Recent Filing)CHF28.85M
Total Debt (Recent Filing)CHF38.13M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Sep 22, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding20,805,798
10 Day Avg. Volume255,106
30 Day Avg. Volume170,297
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-45.95
Price to Sales (P/S)26.73
P/FCF Ratio15.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF44.00Price Target Upside167.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.97
Revenue Forecast (FY)CHF24.62M
Bulls Say, Bears Say
Bulls Say
Strategic Partnership & FundingThe Eisai licensing deal delivered EUR 48m upfront and access to up to EUR 38m more (EUR 15m already in bank, EUR 11m expected), and deferred EIB repayments. This materially improves near-term non-dilutive runway, lowering immediate refinancing risk and enabling execution of pivotal trials.
Large Global Pivotal ProgramA broad, multi-study Phase III program (>1,300 patients) creates a substantial evidence base and reduces single-study binary risk. Successful 12-week readouts and planned NDA timing would provide durable regulatory de-risking and clearer commercial path for evenamide across multiple jurisdictions.
Strengthened IP PositionA granted European crystalline patent and pursuit of U.S. prosecution could materially extend market exclusivity into the mid-2040s. Stronger IP protection supports long-term commercial returns and partner interest, increasing the value of future royalties and licensing beyond initial launch years.
Bears Say
Elevated Balance-sheet RiskNegative equity and high leverage constrain strategic flexibility: refinancing or additional M&A/partnering options become harder, and downside shocks increase dilution/refinancing risk. This structural weakness limits the firm's ability to self-fund commercialization or absorb trial setbacks over the medium term.
Volatile, Lumpy RevenuesRevenue depends on irregular license/milestone receipts, producing large year-to-year swings and episodic profitability. This lumpy cash profile undermines predictability for R&D and commercial investments and increases reliance on external funding or milestone timing to sustain operations beyond pivotal readouts.
Dependence On Trial Outcomes/funding TriggersSignificant near-term funding is conditional on positive trial results, and enrollment/site initiation has faced delays. This creates structural execution risk: negative or delayed readouts could remove expected cash, compress runway, force dilutive financings, and slow commercialization timelines.
Newron Pharmaceuticals SpA News
NWRN FAQ
What was Newron Pharmaceuticals SpA’s price range in the past 12 months?
Newron Pharmaceuticals SpA lowest stock price was CHF6.50 and its highest was CHF31.85 in the past 12 months.
What is Newron Pharmaceuticals SpA’s market cap?
Newron Pharmaceuticals SpA’s market cap is CHF254.25M.
When is Newron Pharmaceuticals SpA’s upcoming earnings report date?
Newron Pharmaceuticals SpA’s upcoming earnings report date is Sep 22, 2026 which is in 93 days.
How were Newron Pharmaceuticals SpA’s earnings last quarter?
Newron Pharmaceuticals SpA released its earnings results on Mar 24, 2026. The company reported -CHF0.608 earnings per share for the quarter, missing the consensus estimate of -CHF0.074 by -CHF0.534.
Is Newron Pharmaceuticals SpA overvalued?
According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Undervalued.
Does Newron Pharmaceuticals SpA pay dividends?
Newron Pharmaceuticals SpA does not currently pay dividends.
What is Newron Pharmaceuticals SpA’s EPS estimate?
Newron Pharmaceuticals SpA’s EPS estimate is -0.17.
How many shares outstanding does Newron Pharmaceuticals SpA have?
Newron Pharmaceuticals SpA has 20,805,798 shares outstanding.
What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?
Newron Pharmaceuticals SpA reported an EPS of -CHF0.608 in its last earnings report, missing expectations of -CHF0.074. Following the earnings report the stock price went down -5.333%.
Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?
Currently, no hedge funds are holding shares in CH:NWRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Newron Pharmaceuticals SpA
Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.
NWRN Company Deck
NWRN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong positive developments: validation from a top-tier partner (Eisai) and EUR 48m collected, a large global pivotal program across >1,300 patients with significant Phase III/Phase II efficacy signals (8A: PANSS p=0.006; CGI-S p=0.037), an improved IP position (European crystalline patent and potential U.S. grant to extend exclusivity to 2044), robust safety/tolerability and clear commercial expansion potential. Management has secured non-dilutive runway and delayed debt service to mid-2028. Principal risks flagged were operational recruitment challenges, parts of funding conditional on positive results (EUR 12m), pending U.S. patent timing, and the fact that a NASDAQ uplisting is not currently achievable without further progress. On balance the highlights (clinical validation, funding, IP progress, safety, analyst coverage) substantially outweigh the lowlights, though the company remains dependent on upcoming pivotal readouts and execution.View all CH:NWRN earnings summariesNWRN Stock 12 Month Forecast
Average Price Target
CHF44.00
▲(167.64% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Xlife Sciences Ltd.
―
Options Prices
Currently, No data available
---